Glaukos (GKOS) Stock Forecast & Price Target

Glaukos is well positioned for long-term growth due to its revolutionary iDose sustained-release drug delivery implant and positive feedback from ophthalmologists, as well as its promising growth potential in the keratoconus market. While the recent LCD draft decision may create some headwinds, the company has a strong referral network and a potential offset from unlocking Medicare Advantage patients. With the potential for double-digit revenue growth and its unique position in the market, GKOS remains an attractive investment opportunity.

Glaukos is facing potential headwinds with the proposed LCDs for their iDose TR implant, which may restrict its use to patients who fail two drops and SLT, and limit its usage in concurrent procedures with other MINOs, which comprise a significant portion of the current iDose volume. This could significantly delay care for patients and also limit the potential benefits of the iDose therapy. Additionally, Glaukos's pricing strategy and corporate greed have raised concerns among physicians and may have a negative impact on patient outcomes. There is also regulatory, clinical, and competitive risks with their pipeline products, as well as macroeconomic headwinds and changing reimbursement policies.